Powered by decades of experience and global cell collection network of the National Marrow Donor Program® (NMDP)/Be The Match®, Be The Match BioTherapies® partners with cell and gene therapy leaders to deliver high-quality, consistent and compliant therapies to more patients in need.
In collaboration with our research arm, the CIBMTR® (Center for International Blood and Marrow Transplant Research®), which has more than 45 years of experience collecting health outcomes data, our services support cellular therapies at every stage of development from clinical research through commercialization and long-term outcomes tracking.
Since inception, the NMDP/Be The Match and the CIBMTR have led the cellular therapy field through the management of:
A timeline of our history:
A year after being established as the United States’ national registry of volunteer bone marrow donors, NMDP/Be The Match manages the first organizational donor search and bone marrow transplant.
NMDP/Be The Match facilitates first successful peripheral blood stem cell transplant, increasing the efficiency and safety of the donation processes.
NMDP/Be The Match launches umbilical cord blood transplant program. Today, there are more than 249,000 cord blood units accessible through the Be The Match Registry®.
Research Sample Biorepository is constructed, one of the world’s largest tissue sample storage facilities for medical research. Today, the Biorepository provides storage for more than 2.5 million sample aliquots.
NMDP/Be The Match partners with the Medical College of Wisconsin to merge research operations into one leading global research program, officially known as the CIBMTR moving forward.
The CIBMTR is awarded the contract for the Stem Cell Therapeutic Outcomes Database (SCTOD) by the Health Resources and Services Administration of the U.S. Department of Health and Human Services, designating them as the database administrator for all U.S. stem cell transplant outcomes.
The CIBMTR completes more than 1,000 peer-reviewed research publications.
NMDP/Be The Match establishes Be The Match BioTherapies® as a natural extension of the mission to save lives through cellular therapy. Through this, Be The Match BioTherapies provides more than 30 years of expertise and proven industry solutions to companies developing next-generation cell and gene therapies.
Be The Match BioTherapies executes contracts to provide cell sourcing and supply chain management services to power the development of allogeneic cell therapies.
Be The Match BioTherapies successfully collects and delivers first cellular therapy starting material for manufacture, less than 2 months after contract is signed.
Be The Match BioTherapies announces a collaboration with Magenta Therapeutics to expand the use of stem cell transplant to immune- and blood-based diseases.
MatchSource® software is launched for managing cell and gene therapy supply chains.
NMDP/Be The Match now includes a contracted network of more than 80 apheresis centers, 70 marrow collection centers, and 180 transplant centers. These extensive relationships provide a solid foundation for Be The Match BioTherapies to develop and manage cell collection networks for clients developing or commercializing cell and gene therapies.
Be The Match BioTherapies begins U.S. and international apheresis center audits for commercial CAR-T Collection Network.
Be The Match BioTherapies invests in Tmunity Therapeutics to support the advancement of next-generation T cell immunotherapies.
Be The Match BioTherapies begins U.S. and international apheresis center network support for commercial CAR-T Collection Network.
Be The Match BioTherapies’ research partner, the CIBMTR, announces a collaboration with Kite to track long-term outcomes data for YESCARTA®.
Be The Match BioTherapies hosts the Cell & Gene Therapy Standardization Summit, bringing together key industry stakeholders to discuss system capacity and needs and opportunities for standardization throughout the industry.
Be The Match BioTherapies launches efforts to establish international standards across the cell and gene therapy industry, prioritizing standardization in apheresis collections, supply chain logistics and outcomes data tracking.